REGENXBIO Inc. (NASDAQ:RGNX) Q3 2021 Earnings Conference Call November 2, 2021 4:30 PM ET Company Participants Patrick Christmas – Chief Legal Officer Ken Mills – President and Chief Executive Officer Steve Pakola – Chief Medical Officer Vit Vasista – Chief Financial Officer Conference Call Participants Gena Wang – Barclays Mani Foroohar – SVB Leerink Vikram Purohit – Morgan Stanley Esther Rajavelu – UBS Dane Leone – Raymond James Luca Issi – RBC Capital Operator Good afternoon and welcome to the REGENXBIO ...

Washington, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-37553 REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1851754 (S ...

Call Start: 16:30 January 1, 0000 5:30 PM ET REGENXBIO Inc. (NASDAQ:RGNX) Q2 2021 Earnings Conference Call August 9, 2021 16:30 ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - President & Chief Executive Officer Steve Pakola - Chief Medical Officer Vit Vasista - Chief Financial Officer Conference Call Participants Alec Stranahan - Bank of America Gena Wang - Barclays Dane Leone - Raymond James Matthew Harrison - Morgan Stanley Luca Issi - RBC Capital Dane Leone - Raymond James Es ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-37553 REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1851754 (State ...

REGENXBIO Inc. (NASDAQ:RGNX) Q1 2021 Results Conference Call May 5, 2021 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - President and CEO Dr. Steve Pakola - Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Gena Wang - Barclays Gbola Amusa - Chardan Esther Rajavelu - UBS Kostas Biliouris - Morgan Stanley Lisa Walter - RBC Operator Good afternoon, and welcome to the REGENXBIO First Quarter 2021 Earnings Conference Call. At this time, all ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-37553 REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) FORM 10-Q (Mark One) Delaware 47-1851754 (State ...

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2020 Earnings Conference Call March 1, 2021 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - President and CEO Steve Pakola - Chief Medical Officer Olivier Danos - Chief Scientific Officer Vit Vasista - CFO Conference Call Participants Esther Rajavelu - UBS Lisa Walter - RBC Capital Operator Good afternoon, and welcome to the REGENXBIO Fourth Quarter and Full Year 2020 Earnings Conference Call. At this time, all participants are in a listen- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37553 REGENXBIO Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...

REGENXBIO, Inc. (NASDAQ:RGNX) Q3 2020 Results Earnings Conference Call November 4, 2020 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - President and CEO Steve Pakola - Chief Medical Officer Vit Vasista - CFO Conference Call Participants Gena Wang - Barclays Gbola Amusa - Chardan Lisa Walter - RBC Capital Markets Gbola Amusa - Chardan Operator Good afternoon and welcome to the REGENXBIO Third Quarter 2020 Earnings Conference Call. At this time, all participants are in a l ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-37553 REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1851754 (S ...